A sub-analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial and accompanying registry indicated that the use of potent ADP-receptor antagonists—predominantly prasugrel—is feasible and might not be harmful in patients with cardiogenic shock complicating AMI [8, 9]. Here, P2RY1 is linked to Shock.